About Biofrontera
Biofrontera is a company based in Leverkusen (Germany) founded in 1997. The company has 93 employees as of December 31, 2024. Biofrontera has completed 1 acquisition, including Cutanea Life Sciences. Biofrontera offers products and services including Photodynamic Therapy Products and Topical Antibiotics. Biofrontera operates in a competitive market with competitors including Revance Therapeutics, Dermavant, Sol-Gel Technologies, SkinMedica and Hugel, among others.
- Headquarter Leverkusen, Germany
- Employees 93 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biofrontera Inc.
-
Annual Revenue
$37.32 M (USD)9.54as on Dec 31, 2024
-
Net Profit
-$17.76 M (USD)11.78as on Dec 31, 2024
-
EBITDA
-$16.06 M (USD)20.83as on Dec 31, 2024
-
Latest Funding Round
$11 M (USD), Post-IPO
Jun 27, 2025
-
Investors
NRW
& 1 more
-
Employee Count
93
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Biofrontera
Biofrontera is a publicly listed company on the NASDAQ with ticker symbol BFRI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Biofrontera
Biofrontera offers a comprehensive portfolio of products and services, including Photodynamic Therapy Products and Topical Antibiotics.
Treatments for pre-cancerous skin lesions using light-based therapy.
Medications for bacterial infections like impetigo.
People of Biofrontera
Unlock access to complete
Funding Insights of Biofrontera
Investors in Biofrontera
Biofrontera has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include NRW and Rosalind Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provides investment management for life sciences and biotech funds to investors worldwide.
|
Locked | Locked | Locked | |
|
Government programs access and development services are provided by NRW.
|
Locked | Locked | Locked |
Investor details for Biofrontera
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biofrontera
Biofrontera has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cutanea Life Sciences.
Investment portfolio details for Biofrontera
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for skin disorders like acne and psoriasis are developed.
|
Locked | Locked | 2005 | Locked |
Complete acquisition details for Biofrontera
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Biofrontera
Detailed financials for Biofrontera
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biofrontera Comparisons
Peer comparison for Biofrontera
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biofrontera
Biofrontera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Dermavant, Sol-Gel Technologies, SkinMedica and Hugel, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| Locked | Locked | Locked |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
|
| Locked | Locked | Locked |
Skin care products are developed and manufactured by SkinMedica.
|
|
| Locked | Locked | Locked |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
Detailed competitors of Biofrontera
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biofrontera
Complete news archive for Biofrontera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biofrontera
Biofrontera was founded in 1997 and raised its 1st funding round 7 years after it was founded.
Biofrontera is headquartered in Leverkusen, Germany. It is registered at Leverkusen, North Rhine-westphalia, Germany.
As of Dec 31, 2024, the latest employee count at Biofrontera is 93.
Annual revenue of Biofrontera is $37.32M as on Dec 31, 2024.
Biofrontera was founded in 1997 in Leverkusen, Germany, and operates within the dermatology sector. Solutions are offered for the sale and distribution of drugs, medical devices, and medical cosmetics focused on the care and treatment of skin diseases. The lead product, Ameluz, is utilized as a prescription drug for treating squamous cell carcinoma in situ. Additional dermatological items, including creams, gels, and scalp tonics, have been developed for consumer use.
Biofrontera's top competitors include Revance Therapeutics, Dermavant and Collplant.
Biofrontera offers Photodynamic Therapy Products and Topical Antibiotics.
Yes, Biofrontera is publicly traded on NASDAQ under the ticker symbol BFRI.
Biofrontera has made 1 acquisition, including Cutanea Life Sciences.
Biofrontera has 2 investors. Key investors include NRW, and Rosalind Advisors.
The ticker symbol of Biofrontera is BFRI on NASDAQ.